About Eckard Weber
Form D filings for Transposon Therapeutics from 2022 to 2024 list Eckard Weber as executive officer and director.
Eckard Weber reports to the SEC as a director of 6 public companies, including Adynxx (ADYX), Ocera Therapeutics (OCRX) and Tobira Therapeutics (TBRA).
Eckard Weber first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Eckard Weber in the role, so the role may have started earlier or lasted longer.
AI
Adynxx, Inc.
Director
2019 · Public company (ADYX)
OI
Ocera Therapeutics, Inc.
Director
2013 – 2017 · Public company (OCRX)
TI
Tobira Therapeutics, Inc.
Director
2015 – 2016 · Public company (TBRA)
OI
Orexigen Therapeutics, Inc.
Director
2007 – 2015 · Public company (OREXQ)
AI
Atara Biotherapeutics, Inc.
Director
2014 – 2015 · Public company (ATRA)
PI
Paratek Pharmaceuticals, Inc.
Director
2006 – 2008 · Public company (PRTK)
Key Colleagues at Startups
The people Eckard Weber works with at each company, as listed on that company's latest Form D.
Transposon Therapeutics, Inc. · Form D, Jul 15, 2024
KK
Keith Katkin
Director
DP
Dennis Podlesak
Chief Executive Officer and director
LR
Lynne Rollins
Executive officer
DM
Daniel Hetu, MD, MBA
Director
BA
Brent Ahrens
Director
BM
Brian Slingsby, MD, PHD, MPH
Director
WM
William Harrington, MD, MBA
Director
JP
John Pacifico
Director